Opinion

Video

Small Cell Lung Cancer: What is the Role of Biomarker Testing?

Shared insight on the early but evolving role of biomarker testing in patients diagnosed with extensive- or limited-stage small cell lung cancer.

Transcript:

Laurent Greiller, MD:What would be interesting is to discuss if we have any predictive or prognostic biomarkers beyond the clinical one I was mentioning to guide our strategies. What do you think, Dr Grohé?

Christian Grohé, MD: In terms of understanding how we are going to treat these patients, you already alluded to the point that patients can present with a very poor [ECOG] performance status. If we can initiate treatment, they do better. Still, at our institution, Charité Comprehensive Cancer Center [in Berlin, Germany], 1 out of 5 patients do not make it to first-line therapy because they’re too sick. Their performance status…is 3 or 4. So this is an interesting issue. What would be the most important biomarker to help guide our treatment options? Honestly, there are a few. Maybe in standup care, something such as LDH [lactate dehydrogenase]. Sometimes if your patient has elevated liver enzymes, [you may] look for neuroendocrine markers, which are circulating. My personal belief is the clinical context is pretty much like it is with a hematology disorder. If you have a very high cell turnover, this is just an indicator of massive disease burden. This is basically what you’re looking for…. We might discuss a little bit later that small cell lung cancer [has] 4 different kinds of subtypes. This is part of the histology and the genetic analysis of the tumor, which does not play a role at the beginning of the first initiation of first-line therapy. We are still at the very beginning of using or having useful biomarkers for all patients with small cell lung cancer, in my opinion. I don’t know if you, Dr Greiller, share this opinion.

Laurent Greiller, MD: I totally agree with you. It’s a subgroup of lung cancer patients in which we’re needing additional biomarkers because honestly, we don’t really have them today.

Christian Grohé, MD:It’s a clinical decision, how to treat and when to treat. It’s pretty much an acute disease. Once we have the diagnosis, we should start.

Transcript edited for clarity.

Related Videos
Steven H. Lin, MD, PhD
2 KOLs are featured in this series.
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.